SynthesisThe Psychiatric quarterly2026
Effect of Curcumin Supplementation on Schizophrenia Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in The Psychiatric quarterly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms pose a significant burden in patients with schizophrenia; currently, there are no specific pharmacological therapies available to helping address this problem. Pilot studies suggest a promising role of curcumin as an adjunct to standard treatment for negative symptoms management, but the totality of clinical evidence remains to be comprehensively assessed. We aimed to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to provide a comprehensive summary of the evidence regarding the effects of curcumin on symptoms in patients with schizophrenia and other psychotic disorders. We performed a systematic search in Pubmed, Scopus, Web of Science, and Cochrane Library from inception to May 2024; no language restriction was applied. Only randomized controlled trials using curcumin as an intervention were included. The certainty of the evidence (CoE) was measured using the GRADE approach. After screening 647 articles and full-text review, four studies were included, all interventions were in patients with schizophrenia. The use of curcumin showed no significant effect on positive (SMD -0.33, 95% CI [-0.76; 0.09], CoE: Low) and total symptoms (SMD -0.47, 95% CI [-1.08; 0.14], CoE: Very low), but a statistically significant decrease on negative symptoms (SMD -0.37, 95% CI [-0.70; -0.03], CoE: Low) and general psychopathology (SMD -0.68, 95% CI [-1.18; -0.17], CoE: Very low) was found. No significant differences were observed for depression (CoE: Very low). Curcumin supplementation as an adjunct to standard treatment may result in a small decrease in negative symptoms in patients with schizophrenia. However, it may have little to no effect on positive symptoms. The evidence for total symptoms, depression and general psychopathology was very uncertain. Due to the low certainty of the evidence, our confidence in these effect estimates is limited, and implementation into clinical practice is not yet recommended. Future studies should be focused on unravelling the molecular targets of negative symptoms regulation to generate specific therapies.
Indexed as
Identifiers
41108513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.